Donna Roy Grogan - C4 Therapeutics, Inc. - Form 4 Filing

This filing details a Form 4 filed by Donna Roy Grogan, a director at C4 Therapeutics, Inc. (CCCC). The transaction, dated June 24, 2026, involves the acquisition of 62,000 stock options with a right to buy Common Stock. The options have an exercise price of $4.25 and are set to expire on June 23, 2036. A key footnote indicates that these options will vest and become exercisable in full on the earlier of June 24, 2027, or the next annual stockholder meeting, provided Grogan remains a Board member on that date. The filing also notes that Grogan holds these options directly.